News from Delphi


Latest news



Delphi advisor to the sellers of Mediaplanet International AB

Delphi has advised the sellers of Mediaplanet International AB in the divestment of all shares to the private equity firm Priveq Investment.   Mediaplanet, founded in 2002, is a media company with a leading market position in campaign-based B2B content marketing. The company has an annual re...

Read more




Delphi advisor when EQT Ventures invests in Watty

Delphi advised EQT Ventures on its investment in Watty.   Delphi’s team was led by managing partner David Aversten and senior associate Emma Dansbo. For more information on the transaction, Watty and EQT Ventures, please see Watty’s press release.

Read more



Delphi assists BRA AB

In 2014 BRA acquired the island Knarrholmen in the archipelago of Gothenburg. On the island there were some simpler settlements and the island lacked municipal water and sewage.   The island is free of cars and is purely for recreation. BRA has been conducting development work which means th...

Read more



Delphi advisor to Dignitana AB (publ) in connection with public issue

Delphi has been legal advisor to Dignitana in connection with a public issue to raise capital of approximately SEK 52.5 million. Dignitana is a world leader in medical scalp cooling. The company manufactures and markets a patented scalp cooling system, DigniCap®. Stockholm Corporate Finance AB ha...

Read more


Delphi advisor to BrainCool AB (publ) in connection with right issue

Delphi has been legal advisor to BrainCool in connection with a right issue of approximately SEK 14.5 million. BrainCool AB (publ) is a Swedish medical device company that has been listed on Aktietorget since May 2014. Delphi’s team consisted of partner Jens Kinnander and senior associate M...

Read more


Delphi advisor to Immunicum AB (publ) in connection with rights issue

Delphi has acted as legal advisor to Immunicum AB (publ) (“Immunicum”) in connection with a rights issue of approximately SEK 111 million and an over-allotment option of approximately SEK 17 million.   Immunicum develops cancer immunotherapies for the treatment of tumor diseases. Immunicum a...

Read more

Popular news